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T cells, genetically modified by chimeric antigen receptors (CAR-T), are endowed with specificity to a desired antigen and are 
cytotoxic to cells expressing the targeted antigen. CAR-T-based cancer immunotherapy is a promising therapy for curing he-
matological malignancy, such as acute lymphoid leukemia, and is promising for extending their efficacy to defeat solid tumors. 
To date, dozens of different CAR-T cells have been evaluated in clinical trials to treat tumors; this necessitates the establish-
ment of guidelines for the production and application of CAR-T cells. However, it is challenging to standardize CAR-T cancer 
therapy because it involves a combination of gene therapy and cell therapy. In this review, we compare the existing guidelines 
for CAR-T cells and discuss the challenges and considerations for establishing guidance for CAR-T-based cancer immuno-
therapy.  
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Immunotherapy has long been a research focus for cancer 
treatment. The adoptive transfer of immune cells is effica-
cious for inhibiting the growth and invasion of cancer cells 
(Rosenberg et al., 2008). Cytotoxicity elicited by effector 
cells contributes to tumor-killing efficacy. By producing 
lymphokine-activated killers, cytokine-induced killers, and 
selecting and expanding tumor-infiltrating lymphocytes, 
researchers have developed and significantly advanced the 
application of cancer immunotherapy, including substan-
tially enhancing the quality of effector cells, for sophisti-
cated clinical utilization. Since the end of 1990s (Gilham  
et al., 2012; Gross et al., 1989; Kuwana et al., 1987), T 
lymphocytes have been genetically equipped with chimeric 
antigen receptors (CAR), by which the specificity of T cells 
can be modulated to a desired antigen. Distinct from un-
modified effector T cells, CAR-modified T (CAR-T) cells 
exert tumor-killing responses in a human leukocyte anti-
gen-independent manner. Another effector cells, Natural 
Killer cells (NK) are redirected by CARs (Li et al., 2015). 
With the development of the first generation CAR construct 
through the third generation, various CAR-T cells have 
been generated to treat different tumors. Currently, more 
than 50 clinical trials involving CAR-T cells to treat cancers 
are under phase I/II studies. Notably, CAR-T cells with 
CD19 specificity showed high efficacy for the treatment of 
refractory/relapsed hematological malignancies (Brentjens 
et al., 2013; Grupp et al., 2013; IKalos et al., 2011; Kochen- 
derfer et al., 2010; Porter et al., 2011). CAR-T-based cancer 
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immunotherapy, along with monoclonal antibodies of im-
mune checkpoints, led a scientific breakthrough in 2013 
(Couzin-Frankel, 2013).  
NECESSITY OF GUIDELINES FOR CAR-T 
CELLS 
It is widely accepted that medical drugs should be regulated 
by specific administration under set guidelines. Guidelines 
for medical drugs should be developed by regulation de-
partments as well as experienced researchers and physi-
cians. Well-established guidelines warrant the quality of the 
product and guarantee the preliminary requirement for safe 
and efficacious applications. Importantly, guidelines sup-
port the advancement of related techniques and accelerate 
the application of regulated products. For CAR-T cells, 
guidance from administration under set guidelines is essen-
tial. Different academic institutions generated CAR-T cells 
with their own modifications, leading to variations in the 
phenotype, biological potency, and other characteristics. 
Therefore, it is important to establish guidelines for man-
dating preliminary requests for CAR-T cells and the pro-
duction process. Indeed, it is challenging to establish 
well-accepted guidelines for the entire CAR-T industry be-
cause clinical data of CAR-T cells with distinct phenotypes 
or production methods often show equal efficacy. The 
guidelines, therefore, are regulations describing the minimal 
and fundamental criteria for production, in-process releas-
ing tests, and certificate analysis (Gee, 2015). 
EXISTING GUIDELINES SUITABLE FOR 
CAR-T CELLS 
Unlike traditional “off-the-shelf” drugs, CAR-T cells have 
unique features. CAR-T cells are somatic cells that are un-
der the regulation guidelines for cell therapy. Their genetic 
modification categorizes them gene therapy products. To 
date, more than 70 clinical trials have been registered, with 
46 trials in the United States and 16 trials in China (data 
according to www.clinicaltrials.gov). These CAR-T cells 
must be regulated by domestic guidelines.  
The Food and Drug Administration (FDA) in United 
States has classified CAR-T cells as 351 biological products 
and regulates them through “Considerations for the design 
of early-phase clinical trials of cellular and gene therapy 
products” and “Guidance for industry: preclinical assess-
ment of investigational cellular and gene therapy products”, 
dated November 2013, direct by the Office of Cellular, Tis-
sue, and Gene Therapies in the Center for Biologics Evalua-
tion and Research. Additionally, CAR-T cells should meet 
the criteria for chemistry, manufacturing, control (CMC) 
information following the released guidance “Guidance for 
FDA reviewers and sponsors: content and review of chem-
istry, manufacturing, and control (CMC) information for 
human somatic cell therapy investigational new drug appli-
cations (INDs)”; dated April 2008 and “Guidance for FDA 
reviewers and sponsors: content and review of chemistry, 
manufacturing, and control (CMC) information for human 
gene therapy investigational new drug applications (INDs); 
dated April 2008”. These regulations direct the manufac-
turing, in-process control, release testing, and quality con-
trol of the CAR-T cells. 
In Europe, the medical administration is regulated by the 
European medicines agency (EMA). The issued guideline 
“Guideline on quality, non-clinical and clinical aspects of 
medicinal products containing genetically modified cells”, 
finalized in 2012, is suitable for CAR-T cells. This guide-
line defines the scientific principles and provides guidance 
for the development and evaluation of medicinal products 
containing genetically modified cells intended for use in 
humans and presented for marketing authorization. The fo-
cus of this guideline is on the quality, safety, and efficacy 
requirements of genetically modified cells developed as 
medicinal products. In addition, the manufacture of CAR-T 
cells should be regulated by the basic guidelines for medical 
products, including the regulation on advanced therapy me-
dicinal products No 1394/2007 and guidance on quality, 
preclinical and clinical aspects of gene transfer medicinal 
products (CPMP/BWP/3088/99). Distinct from FDA’s 
guidelines, EMA issued specific documents to regulate ge-
netically modified cells as medical products.  
The China Food and Drug Administration issued a panel 
of guidelines for gene and cell therapy. In 2003, a guideline 
named the “Guideline for research and quality control 
technology of human gene therapy products” was issued. 
This document defines the basic requirements for medical 
products under consideration for clinical trials. In this 
guideline, medical products are specified as genetically 
modified cells and vectors (viral and non-viral) carrying 
functional genes. CAR-T cells products should be regulated 
by this guideline. As a cellular therapy products, CAR-T 
cells should also be regulated by the “Guidelines for re-
search and quality control technology of human somatic 
cellular therapy products”, issued in 2003. For clinical ap-
plication, CAR-T cell products are regulated by the univer-
sal guideline for drugs applying for clinical trials, the 
“Quality management standard for drugs applying for clini-
cal trials”, issued by the China Food and Drug Administra-
tion in August 2003. In fact, CAR-T cells have some unique 
characteristics that are beyond the regulation of current 
guidelines, but are necessary for their safety and biological 
potency, such as the transduction efficiency. With the re-
lease of guidelines unique for stem cells for clinical trials in 
2015, administrative documents specific for CAR-T cells 
are expected to be issued in China. 
Nations allowing clinical trials of CAR-T cells issue their 
own domestic guidelines. To merge their regulatory experi-
ences, interexchange between administrations of different 
nations often occurs, such as between the FDA and EMA. It 
is clear that CAR-modified T cells should be regulated by 
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different guidelines within one nation, and there are specific 
administrative documents suitable for CAR-T cells. A good 
guideline should guarantee the requirement for safety and 
enable maximum efficacy. 
KEY ASPECTS OF CAR-T CELL PRODUCTS 
MUST BE REGULATED 
The production of CAR-T cells involves vector production, 
modification of T lymphocytes, and expansion of CAR-T 
cells. Standard operation protocols should be established 
and good manufacturing practice facilities are required. 
During the entire production process, detailed in-process 
control parameters and release testing standards are defined 
to regulate the production of CAR-T cells (Figure 1). Before 
modifying T cells, vectors carrying CAR genes have to be 
produced. The uniformity and homogeneity are determined, 
and the T cells are separated. The entire process is moni-
tored in two parts, a vector-producing part and a CAR-T 
cell-producing part. The first part is typically regulated by  
the guidelines issued for gene therapy products, while the  
second part is always regulated by the guidelines issued for 
cellular therapy and gene therapy. Although there are nu-
merous minor differences between the guidelines regulating 
CAR-T cells in different nations, the main aspects to be 
regulated are similar. 
Materials 
All materials for CAR-T cells production (including the 
reagents used for vector production) should be clinical 
grade if available. The materials and reagents should be 
high-quality, including testing of sterility, and free of endo-
toxins and adventitious contaminations. Detailed infor-
mation regarding the materials should be recorded, includ-
ing the supplier, lot number, and expiration date. If the vec-
tor used to transduce T cells is provided by a manufacturer, 
detailed information should be provided along with the 
vectors. Culture media should be serum-free if possible. If 
the serum is indispensable, documents validating the neces-
sity of the serum should be provided. Similarly, it is strong- 
 
 
Figure 1  Schematic illustration of the CART manufacturing process and the quality control of each step regulated by current guidelines. Peripheral blood 
mononuclear cells are selected from whole blood and activated. Activated T cells are transduced with CAR retroviral/lentiviral vectors or transpos-
ons/mRNA. Modified cells are expanded using an appropriate bioreactor, such as a WAVE bioreactor. Magnetic Dynabeads are removed from the cells with 
MPC and then the cells are evaluated for infusion. Each step regulated by the guidelines is boxed with a dotted line. 
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ly recommended that other additives such as cytokines, an-
tibiotics, and others, be removed.  
Vector production 
Viral vectors, including lentivirus and retrovirus, are the 
most commonly used vectors for transducing T cells into 
CAR-T. Electroporation of mRNA, DNA, and the trans-
poson/transposase system also showed efficient transduc-
tion of T cells. When used with viral vectors, the produc-
tion, collection, and purification steps should be monitored. 
Banking systems should be established where the master 
cell bank and working cell bank are requisites. Quality con-
trol of the plasmids used to generate single infectious pseu-
do-virus must be validated and plasmid constructs should be 
verified before the production step. Appropriate purification 
technology should be established to meet the releasing cri-
teria under the guideline of gene therapy products. Finally, 
quality control of the vectors should be validated, including 
testing for sterility, endotoxins, identity, purity, absence of 
replicative component vectors, genome integration manner, 
and infectious potency.  
When used with electroporation, the quality control of 
the mRNA or DNA plasmids is mandated. The device 
should be clinically applicable, and the buffer reagents 
should be clinical grade if possible. 
Modification of T cells 
Viral and non-viral modifications cause genomic toxicity 
(Verma and Somia, 1997). Viral vectors always integrate 
transgenes into T cells, and the absence of insertional mu-
tagenesis and recombinant virus components should vali-
dated (Hacein-Bey-Abina et al., 2003), although previous 
studies have demonstrated non-preferred integration sites by 
lentiviral vectors (Aiuti et al., 2013; Biffi et al., 2013). After 
the emergence of the recombinant virus component, the 
entire batch should be discarded. In order to minimize ge-
nomic toxicity, a minimal multiplicity of infection is sug-
gested, provided that the transduction efficiency is not af-
fected by the use of viral vectors. Viability, phenotype, ste-
rility, and homogeneity of the modified cells must be de-
termined. Transduction efficiency should be determined by 
flow cytometry or equivalent methods. The gene copy 
number per cell should be determined. In addition, the ex 
vivo proliferation and expansion capacity and genetic stabil-
ity of the modified cells are recommended to be determined. 
Clinical considerations 
Clinical considerations are the final step of the CAR-T cell 
application. Well-established regulations facilitate the clin-
ical management and benefit maximization of CAR-T based 
therapy. Approval from national or local ethics committees 
is a preliminary requisite. Inclusion and exclusion criteria 
must be established before the start of the trial. Any modi-
fications to the criteria should be approved by the commit-
tee and recorded appropriately. Detailed information re-
garding the patients should be recorded over the long-term, 
such as 20–30 years. Dosage, timeline, course, and infusion 
pathway must be recorded. Efficacy should be evaluated 
appropriately. Toxicity and adverse effects must be moni-
tored during the entire course or longer, and the corre-
sponding procedures for dealing with adverse effects should 
be well-designed. Clinical follow-up is required for clinical 
trials of CAR-T cell therapy to monitor the efficacy and 
early or delayed risks.  
CHALLENGES TO ESTABLISHING 
GUIDELINES 
Typically, guidelines are established as universal regula-
tions that determine the basic quality standard for medical 
products. The threshold of criteria should not be so high that 
application of the CAR-T therapy is limited, but the quality 
standard should be as high as possible to minimize risks. It 
is therefore challenging to devise well-accepted guidelines 
for CAR-T cells and there are always dilemmas when de-
signing the guidance. A balance between encouragement 
and restriction is required. The following aspects presented 
challenges, due to uncertainty and complexity of CAR-T 
cells, when establishing the guidelines and will be opti-
mized with the development of CAR-T cell-based immuno-
therapy. 
Transduction efficiency and optimal population 
The percentage of CAR-positive T cells is an important 
parameter of CAR-T cell products. Current guidelines re-
quire determination of transduction efficiency by flow cy-
tometry or equivalent pathways. However, whether the in 
vivo efficacy is related to transduction efficiency or the ap-
propriate level of efficacy is controversial. Previous studies 
indicated that transduction less than 10% had a strong and 
persistent anti-tumor response (IKalos et al., 2011; Porter  
et al., 2011). Thus, there is no threshold for transduction 
efficiency in all existing guidelines, although recording this 
parameter is required.  
It is technically easy to produce pure CAR-positive T 
cells by incorporating antibiotic-resistant genes into the 
CAR vector and selecting CAR-T cells with the corre-
sponding antibiotics. However, incorporation of antibi-
otic-resistant genes is not suggested in issued guidelines; 
hence, few CAR-T cells under clinical trials have incorpo-
rated these genes. Since CD8+ effector cells show efficacy 
in the immune response, it is reasonable that infused CD8+ 
CAR-T cells have superior efficacy compared to other pop-
ulations, but previous studies demonstrated that CD4+ 
CAR-T cells are essential for the tumor-killing efficacy 
(Tsuji et al., 2005). Recent studies suggested that CAR-T 
cells bearing the phenotype of central memory effector cells 
are likely key for the efficacy because of their improved in 
vivo survival and persistence (Riddell et al., 2014), although 
others reported that naïve memory cells are more potent 
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(Hinrichs et al., 2010). It remains to be determined whether 
there is an optimal infused population of CAR-T cells. It is 
suggested that the regulatory T cells subset be removed be-
cause they inhibit CAR-T function (Lee et al., 2011; Yao  
et al., 2012). Increasing evidence has suggested that im-
mune-checkpoints, such as programed cell death protein 1 
and cytotoxic T-lymphocytes-associated protein 4, inhibit 
the potency of CAR-T cells (Deng et al., 2014; Peng et al., 
2012). Whether these checkpoints in CAR-T cells can be 
used to predict the clinical response, and whether it is nec-
essary to establish a threshold for the expression level of 
these immunosuppressive checkpoints on CAR-T cells in 
the guidelines are under consideration.  
Variations 
Unlike “off-the-shelf” products, CAR-T cells are personal-
ized medical products. From collecting T cells to infusing 
final CAR-T cells into patients, it is difficult to establish 
universal standards because of patient-to-patient variation. 
Populations of apheresis products from different patients 
vary and transduction efficiencies differ even when the 
same multiplicity of infection is used. After CAR modifica-
tion, different proliferation capacities emerged, leading to 
varying ex vivo culture times to obtain a specific number of 
infused cells.  
Scale-up production of vectors and stable aliquot storage 
are strongly recommended to maintain the transduction po-
tency. However, gradually decreasing potency is common 
over extended storage time, resulting in variations in trans-
duction efficiency. 
Biological potency 
The issued guidelines must state that the biological potency 
of CAR-T cells must be tested before infusion. Lytic activi-
ty or the release of inflammatory cytokines when encoun-
tering target cells is frequently used as an indicator of the 
biological potency of CAR-T cells. Current guidelines do 
not specify the methods that should be used to determine the 
biological potency of CAR-T cells. There are always dis-
crepancies between ex vivo and in vivo efficacies because of 
various factors, necessitating comprehensive evaluation of 
the ex vivo biological function. Both lytic function and cy-
tokine release should be tested. Many modifications have 
been made to CAR-T cells, including the ability to release 
interleukin-12 or other cytokines and chemokine receptor 
overexpression (Chinnasamy et al., 2012; Chmielewski  
et al., 2011; Moon et al., 2011; Pegram et al., 2012). These 
modifications increase the complexity of release testing for 
CAR-T cells. The expression levels of molecules that en-
hance the biological potency of CAR-T cells must be de-
termined, and universal, well-accepted methods should be 
established.  
Clinical challenges 
Clinical considerations are important for the efficacy of 
CAR-T cells, including the dosage, pre-conditioning, clini-
cal efficacy evaluation, follow-up, toxicity classification 
and approach, bio-distribution, and other factors. Some of 
these considerations are specified in the current guidelines 
and some are not. Moreover, with the development and op-
timization of CAR-T cells, the regulations for these factors 
should be updated in the guidelines. 
In phase I clinical trials, infused CAR-T cells are typi-
cally split into three dose (10%, 30%, and 60%) in an in-
creasing manner and infused over three days. All CAR-T 
cells can be infused into the patient at once. The total num-
ber of CAR-T cells infused varies from 108 to 1010, calcu-
lated based on the weight or body surface area. The number 
of infused CAR-T cells can also be determined by the 
CAR-positive population. However, in current guidelines, 
there are no suggestions regarding the dosage, design, and 
amount needed for infusion. It is challenging to provide 
detailed requirements for these factors since the optimal 
dosage, design, and calculation method for infused CAR-T 
cells are unclear.  
Previous studies demonstrated that pre-conditioning sub-
stantially improves the clinical response to cell therapy. Pre- 
conditioning, which always involves a non-myeloablative 
chemotherapy regimen, creates a therapeutic “window” for 
CAR-T cells as it removes various suppressive factors that 
inhibit anti-tumor activities. In the current guidelines suita-
ble for CAR-T cells, pre-conditioning is not required. Given 
the increasing amount of pre-clinical and clinical data 
demonstrating the enhancement of efficacy, nearly all re-
cently registered clinical trials have adopted pre-condition- 
ing as a standard strategy prior to CAR-T cell infusion. It is 
thought that future updates of the guidelines will take 
pre-conditioning into consideration. 
It is challenging to include clinical efficacy evaluation 
into the guidelines for CAR-T cells. The response evalua-
tion criteria in solid tumors (RECIST) are a set of published 
rules that define improvement conditions for cancer patients 
after receiving a specific treatment. RECIST was developed 
and published in 2000 and updated in 2009. Most world-
wide clinicians determine efficacy using these criteria. Alt-
hough the current guidelines suitable for CAR-T cells have 
no specific efficacy evaluation guidelines, it is strongly 
recommended that potency be evaluated by RECIST. For 
non-solid malignancy, corresponding criteria are needed. 
Clinical follow-up is essential for CAR-T cell-based thera-
py. As a gene therapy product, a long-term (15 years or 
longer) follow-up schedule should be established to evalu-
ate efficacy and safety. 
Toxicity is an important consideration in clinical trials, 
particularly in early phase trials. Current guidelines require 
investigators to design comprehensive and detailed evalua-
tion criteria for toxicity, including classification of toxicity 
with different grades and well-designed strategies for deal-
ing with each grade. The toxicity of CAR-T cell-based im-
munotherapy varies and can be classified as “on-target”, 
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“on-target, off tumor”, and “off-target” adverse effects 
(Wang and Wang, 2012). Cytokine release syndrome, or 
cytokine storm, causes adverse effects. Steroids and other 
immunosuppressive drugs must be prepared in cases of cy-
tokine release syndrome and severe adverse effects. The 
monoclonal antibody blocking interleukin-6 receptor sig-
nificantly reduced the risk of CAR-T cell-based immuno-
therapy (Grupp et al., 2013). Other monitoring and care 
should also be taken into consideration. 
OUTLOOKS 
CAR-T cell-based cancer immunotherapy is a promising 
treatment for cancer. With the rapid enrollment in current 
clinical trials, it is urgent to establish and optimize guide-
lines suitable for CAR-T cells. Given the complexity and 
novelty this therapy, such work is challenging. Currently, 
there are no guidelines specific for CAR-T cells, but the 
guidelines issued for gene and cell therapy products can be 
utilized. Using the extensive findings and experiences 
gained from pre-clinical investigations and clinical trials, 
guidelines for CAR-T cells can be updated and optimized to 
provide substantial clinical benefits to cancer patients.  
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